Colin R. Green
Company: University of Auckland/OcuNexus Therapeutics, Inc. & InflammX Therapeutics, Inc.
Job title: Professor/Chief Scientist
Inflammasome Targeting in Ocular & Neurodegenerative Disease 9:30 am
Connexin hemichannel regulation prevents ATP induced activation of the inflammasome Connexin hemichannel regulation on its own is sufficient to shut down the inflammasome in ocular and neurodegenerative disease InflammX Therapeutics clinical trial plans and progressRead more
day: Day Two